FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950207837> ?p ?o ?g. }

• W2950207837 abstract "Background Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The impact of methotrexate (MTX) withdrawal in patients (pts) with RA who achieve low disease activity (LDA) or remission following treatment with tofacitinib in combination with MTX is unclear. Objectives To compare the efficacy and safety of tofacitinib modified-release (MR) 11 mg once daily (QD) with and without MTX in pts with RA who have achieved LDA with tofacitinib and MTX. Methods ORAL Shift (NCT02831855) was a global Phase 3b/4 study in pts aged ≥18 years with moderate to severe RA and an inadequate response to MTX. Pts received open-label (OL) tofacitinib MR 11 mg QD with MTX (tofacitinib + MTX) for 24 weeks. Pts achieving LDA (CDAI ≤10) at Week (W)24 entered the 24-week double-blind (DB) MTX withdrawal phase and were randomised 1:1 to receive tofacitinib MR 11 mg QD with placebo (tofacitinib monotherapy; ie underwent blinded MTX withdrawal) or continue tofacitinib + MTX. The primary endpoint was least squares mean change from W24 to W48 (Δ; DB phase) in DAS28 4(ESR). Non inferiority of tofacitinib monotherapy vs tofacitinib + MTX was declared if the upper bound of the 95% two-sided confidence interval (CI) for the difference in ΔDAS28-4(ESR) between arms was Results Of 694 pts in the OL phase, 530 achieved CDAI-defined LDA at W24 and were treated in the DB phase (tofacitinib monotherapy: n=264; tofacitinib + MTX: n=266). Demographics and pt characteristics at OL-phase baseline were similar between treatment arms. The difference (95% CI) between arms in ΔDAS28 4(ESR) (primary endpoint) was 0.30 (0.12, 0.48; Table 1) at W48, demonstrating that tofacitinib monotherapy was non-inferior to tofacitinib + MTX. Consistent with the primary endpoint, ΔDAS28-4(CRP)/SDAI/CDAI were greater for tofacitinib monotherapy vs tofacitinib + MTX, but these differences were not clinically meaningful; ACR/HAQ-DI response and LDA rates were generally similar between arms (Table). Remission rates were also similar between arms and generally did not change after MTX withdrawal. In the DB phase, rates of AEs, serious AEs, discontinuations due to AEs and AEs of special interest were generally comparable between arms (Table 1). Conclusion Pts receiving tofacitinib MR 11 mg QD + MTX who achieve LDA may withdraw MTX up to W48 without significant worsening of disease activity. Pts in remission tend to remain in remission after MTX withdrawal. Safety appeared consistent with the known profile of tofacitinib. Reference [1] Felson DT et al. Arthritis Rheum 2011;63:573-586 Acknowledgement Study sponsored by Pfizer Inc. Medical writing support was provided by C Viegelmann of CMC Connect and funded by Pfizer Inc. Disclosure of Interests Stanley B. Cohen Grant/research support from: AbbVie, Eli Lilly, Genentech, Gilead, Pfizer Inc, Consultant for: AbbVie, Eli Lilly, Genentech, Gilead, Pfizer Inc, Janet Pope Grant/research support from: Bristol-Myers Squibb, Roche, Seattle Genetics, UCB, Consultant for: AbbVie, Actelion, Amgen, Bayer, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer Inc, Roche, Sandoz, Sanofi, UCB, Boulos Haraoui Grant/research support from: AbbVie, Pfizer Inc, Consultant for: AbbVie, Amgen, Eli Lilly, Merck, Pfizer Inc, UCB, Fedra Irazoque-Palazuelos Consultant for: Bristol-Myers Squibb, Janssen, Pfizer Inc, Roche, UCB, Mariusz Korkosz Consultant for: AbbVie, Lilly, MSD, Novartis, Roche, UCB, Annette Diehl Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Jose Luis Rivas Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Tatjana Lukic Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Shixue Liu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Lori Stockert Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Noriko Iikuni Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Edward Keystone Grant/research support from: AbbVie, Amgen, Lilly Pharmaceuticals, Pfizer Inc, PuraPharm, Sanofi-Aventis, Consultant for: AbbVie, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Celltrion, Crescendo Bioscence, F. Hoffman-La Roche, Genentech, Gilead, Janssen, Lilly Pharmaceuticals, Merck, Pfizer Inc, Sandoz, Sanofi-Genzyme, Samsung Bioepis, UCB, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb Canada, F. Hoffman-La Roche, Janssen, Merck, Pfizer Inc, Sanofi-Genzyme, UCB" @default.
• W2950207837 created "2019-06-27" @default.
• W2950207837 creator A5006303399 @default.
• W2950207837 creator A5006954047 @default.
• W2950207837 creator A5008899221 @default.
• W2950207837 creator A5023213876 @default.
• W2950207837 creator A5027850805 @default.
• W2950207837 creator A5030150540 @default.
• W2950207837 creator A5030754645 @default.
• W2950207837 creator A5057538503 @default.
• W2950207837 creator A5058868191 @default.
• W2950207837 creator A5060125727 @default.
• W2950207837 creator A5080646462 @default.
• W2950207837 creator A5085262399 @default.
• W2950207837 date "2019-06-01" @default.
• W2950207837 modified "2023-09-26" @default.
• W2950207837 title "LB0004 METHOTREXATE WITHDRAWAL IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVE LOW DISEASE ACTIVITY WITH TOFACITINIB MODIFIED-RELEASE 11 MG ONCE DAILY + METHOTREXATE: A RANDOMISED NON-INFERIORITY PHASE 3B/4 STUDY" @default.
• W2950207837 doi "https://doi.org/10.1136/annrheumdis-2019-eular.8657" @default.
• W2950207837 hasPublicationYear "2019" @default.
• W2950207837 type Work @default.
• W2950207837 sameAs 2950207837 @default.
• W2950207837 citedByCount "0" @default.
• W2950207837 crossrefType "proceedings-article" @default.
• W2950207837 hasAuthorship W2950207837A5006303399 @default.
• W2950207837 hasAuthorship W2950207837A5006954047 @default.
• W2950207837 hasAuthorship W2950207837A5008899221 @default.
• W2950207837 hasAuthorship W2950207837A5023213876 @default.
• W2950207837 hasAuthorship W2950207837A5027850805 @default.
• W2950207837 hasAuthorship W2950207837A5030150540 @default.
• W2950207837 hasAuthorship W2950207837A5030754645 @default.
• W2950207837 hasAuthorship W2950207837A5057538503 @default.
• W2950207837 hasAuthorship W2950207837A5058868191 @default.
• W2950207837 hasAuthorship W2950207837A5060125727 @default.
• W2950207837 hasAuthorship W2950207837A5080646462 @default.
• W2950207837 hasAuthorship W2950207837A5085262399 @default.
• W2950207837 hasBestOaLocation W29502078371 @default.
• W2950207837 hasConcept C126322002 @default.
• W2950207837 hasConcept C142724271 @default.
• W2950207837 hasConcept C203092338 @default.
• W2950207837 hasConcept C204787440 @default.
• W2950207837 hasConcept C27081682 @default.
• W2950207837 hasConcept C2777575956 @default.
• W2950207837 hasConcept C2778886723 @default.
• W2950207837 hasConcept C2781059491 @default.
• W2950207837 hasConcept C31760486 @default.
• W2950207837 hasConcept C535046627 @default.
• W2950207837 hasConcept C71924100 @default.
• W2950207837 hasConcept C90924648 @default.
• W2950207837 hasConcept C98274493 @default.
• W2950207837 hasConceptScore W2950207837C126322002 @default.
• W2950207837 hasConceptScore W2950207837C142724271 @default.
• W2950207837 hasConceptScore W2950207837C203092338 @default.
• W2950207837 hasConceptScore W2950207837C204787440 @default.
• W2950207837 hasConceptScore W2950207837C27081682 @default.
• W2950207837 hasConceptScore W2950207837C2777575956 @default.
• W2950207837 hasConceptScore W2950207837C2778886723 @default.
• W2950207837 hasConceptScore W2950207837C2781059491 @default.
• W2950207837 hasConceptScore W2950207837C31760486 @default.
• W2950207837 hasConceptScore W2950207837C535046627 @default.
• W2950207837 hasConceptScore W2950207837C71924100 @default.
• W2950207837 hasConceptScore W2950207837C90924648 @default.
• W2950207837 hasConceptScore W2950207837C98274493 @default.
• W2950207837 hasLocation W29502078371 @default.
• W2950207837 hasOpenAccess W2950207837 @default.
• W2950207837 hasPrimaryLocation W29502078371 @default.
• W2950207837 hasRelatedWork W2335614809 @default.
• W2950207837 hasRelatedWork W2737739855 @default.
• W2950207837 hasRelatedWork W2749276380 @default.
• W2950207837 hasRelatedWork W2754043363 @default.
• W2950207837 hasRelatedWork W2754454361 @default.
• W2950207837 hasRelatedWork W2755049090 @default.
• W2950207837 hasRelatedWork W2755836038 @default.
• W2950207837 hasRelatedWork W2808240072 @default.
• W2950207837 hasRelatedWork W2808323690 @default.
• W2950207837 hasRelatedWork W2808567002 @default.
• W2950207837 hasRelatedWork W2896812857 @default.
• W2950207837 hasRelatedWork W2900635510 @default.
• W2950207837 hasRelatedWork W2910355860 @default.
• W2950207837 hasRelatedWork W2910517343 @default.
• W2950207837 hasRelatedWork W2947142015 @default.
• W2950207837 hasRelatedWork W2952717710 @default.
• W2950207837 hasRelatedWork W3095584460 @default.
• W2950207837 hasRelatedWork W3123452764 @default.
• W2950207837 hasRelatedWork W3164519483 @default.
• W2950207837 hasRelatedWork W3164788343 @default.
• W2950207837 isParatext "false" @default.
• W2950207837 isRetracted "false" @default.
• W2950207837 magId "2950207837" @default.
• W2950207837 workType "article" @default.